1. Home
  2. Press release
Nov 18, 2020 20:00 JST

Source: Eisai

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
A once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies

TOKYO, Nov 18, 2020 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with prior regulatory approval by the Japanese Ministry of Health, Labour and Welfare.

Jyseleca is indicated for RA (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. The therapy has received approval in Japan and Europe.

Based on a co-promotion agreement entered into by Gilead and Eisai in December 2019, Gilead will hold the marketing authorization of Jyseleca, while Eisai will be responsible for product distribution of Jyseleca in Japan. The companies will collaborate in product information provision activities in Japan.

"It is estimated that approximately 600,000 to 1 million people1 are living with RA across Japan," said Luc Hermans, MD, President and Representative Director, Gilead Sciences, K.K. "While RA treatment is advancing, many patients still do not experience sufficient disease remission, and many unmet medical needs remain. Gilead and Eisai are committed to delivering the new treatment option Jyseleca and supporting RA patients in Japan."

"Eisai has extensive clinical development and commercialization experience in RA and has established a solid RA franchise in Japan," said Hidenori Yabune, President of Eisai Japan, Senior Vice President, Eisai. "With the launch of Jyseleca, we will make further contributions to meet the diverse needs of RA patients and improve their QOL (quality of life)."

Multiple clinical trials are being conducted to investigate the potential role of filgotinib in a variety of diseases, including the Phase 3 SELECTION program in ulcerative colitis and the Phase 3 DIVERSITY program in Crohn?s disease. The safety and efficacy of filgotinib has not been demonstrated for these uses.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company?s website at www.gilead.com(New Window).

For more information on Gilead Sciences K.K., please visit the company?s website at https://www.gilead.co.jp/

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
 
More Press release >>

Latest Press Release


Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 24, 2026 00:00 JST

TOYOTA GAZOO Racing Announces GR Yaris Sebastien Ogier 9x World Champion Edition
Jan 23, 2026 19:26 JST

NEC Develops New 5G Base Station Radio Unit for Enhanced Communication Throughput, Compactness, and Energy Efficiency
Jan 23, 2026 15:00 JST

GlobalLogic and Elektrobit Strengthen Partnership to Accelerate Next-Generation Software-Defined Vehicles
Jan 23, 2026 14:12 JST

Fujitsu and Mizuho Bank partner to develop new order and payment processing service for SMEs
Jan 22, 2026 11:30 JST

TANAKA PRECIOUS METAL TECHNOLOGIES to Exhibit Advanced Precious Metal Materials for Medical Device Components at MD&M West 2026
Jan 21, 2026 22:00 JST

Honda to Discontinue Production of Fuel Cell Systems at Fuel Cell System Manufacturing LLC in the U.S.
Jan 21, 2026 17:44 JST

Notice regarding the dissolution of the joint venture in the home elevator business
Jan 21, 2026 17:04 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 21, 2026 16:44 JST

MHI and ITB Deepen Research Collaboration on Ammonia-Based Clean Power in Indonesia
Jan 21, 2026 16:37 JST

Asian Financial Forum opens next Monday with a fresh perspective and new tagline, Finance Empowering Business
Jan 21, 2026 14:30 JST

MHI-TC Delivers Self-Propelled Mobile Seaport Passenger Boarding Bridge to Yokohama City, Entering Service on January 13th
Jan 21, 2026 11:02 JST

From Computing Chips to Physical AI: Nobel Laureate Hassabis' Trillion-Dollar Paradigm Forecast and 51WORLD's (6651.HK) Industry Breakthrough
Jan 21, 2026 10:00 JST

Overview of Speeches Delivered at Launch Event for New Partnership between Honda and the Aston Martin Aramco Formula One(R) Team for 2026 Season
Jan 20, 2026 14:19 JST

Mitsubishi Motors Marks Record Sales in Vietnam for the Second Consecutive Year in 2025
Jan 20, 2026 12:35 JST

Fujitsu recognized by World Economic Forum for project promoting sustainable hospital management leveraging AI
Jan 20, 2026 11:23 JST

DENSO to Promote Standardization of Automotive Software as an AUTOSAR Core Partner
Jan 19, 2026 16:00 JST

Building the data infrastructure for next-generation materials science
Jan 19, 2026 09:00 JST

New-look TGR-WRT launches landmark campaign on legendary rally
Jan 16, 2026 21:34 JST

Mitsubishi Corporation Announces Acquisition of Haynesville Shale Gas Business in Louisiana and Texas
Jan 16, 2026 21:12 JST
 More Latest Release >>